Product Details
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia vera without symptomatic splenomegaly.
BESREMi® 250 micrograms/0.5 mL solution for injection in pre-filled pen.
Drug Facts
Ropeginterferon alfa-2b
BESREMi® is indicated as monotherapy in adults for the treatment of Polycythaemia vera without symptomatic splenomegaly.
BESREMi® 250 micrograms/0.5 mL solution for injection in pre-filled pen.
Ropeginterferon alfa-2b